CN104523873A - 一种治疗痛风的药物组合物 - Google Patents
一种治疗痛风的药物组合物 Download PDFInfo
- Publication number
- CN104523873A CN104523873A CN201510062971.3A CN201510062971A CN104523873A CN 104523873 A CN104523873 A CN 104523873A CN 201510062971 A CN201510062971 A CN 201510062971A CN 104523873 A CN104523873 A CN 104523873A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- preparation
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 22
- 239000008187 granular material Substances 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000002552 dosage form Substances 0.000 claims abstract description 3
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 239000006187 pill Substances 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 13
- 241000903946 Clematidis Species 0.000 claims description 11
- 239000009636 Huang Qi Substances 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000012467 final product Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000218158 Clematis Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 241001289529 Fallopia multiflora Species 0.000 abstract 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract 1
- 241000229179 Ledebouriella Species 0.000 abstract 1
- 241000195954 Lycopodium clavatum Species 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 230000031864 metaphase Effects 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 238000002156 mixing Methods 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 5
- 231100000862 numbness Toxicity 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 229960001855 mannitol Drugs 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000001047 pyretic effect Effects 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940013618 stevioside Drugs 0.000 description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 4
- 235000019202 steviosides Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000000203 Salix gracilistyla Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了一种治疗痛风的药物组合物,其特征在于该药物组合物处方重量份数计为:忍冬藤1-15份,虎杖1-10份,茯苓1-10份,伸筋草1-10份,黄芪1-10份,淫羊藿1-8份,威灵仙1-8份,车前子1-8份,何首乌1-8份,防风1-8份,甘草1-5份。该药物组合物制剂由中药组合物与药学上可接受的载体组成,剂型包括水煎剂、丸剂、胶囊剂、颗粒剂、冲剂和口服液。本发明组合物对于早、中期痛风患者疗效显著,无毒副作用。
Description
技术领域
本发明属于中药制剂领域,具体涉及一种治疗痛风的药物组合物。
背景技术
痛风的发生是由于体内产生尿酸过多及肾脏清除能力下降,尿酸体内蓄积,导致尿酸盐结晶在关节及各脏器沉积。随着人们生活水平的不断提高、 饮食结构和生活习惯 ( 富含核蛋白的食物增多 )的改变、平均寿命的延长、人类对痛风的认识和诊断水平的提高,无论是在欧美国家还是在亚洲各国, 痛风的患病率都有逐年增高的趋势,目前我国高尿酸血症患者人数超过1.5亿,其中痛风患者超过7500万人,而且以每年0.97%年增长率增加,痛风已成为我国同糖尿病一样的第二大代谢类疾病,并严重威胁着人们的生命和健康。
古代中医医家对痛风的认识可以追溯到《内经》,其间多归于“热痹”的范畴,其名首见于《素问·四时刺逆论》,其中还提出了热痹形成的机理为“其热者,阳气多,阴气少,病气盛,阳遭阴,故为痹热。”所谓痹热,是热痹出现的以关节肿胀、灼热、疼痛、屈伸不利,伴有发热为临床表现的痹病。现代不少医家在前人的基础之上,通过广泛实践,对痛风的病因病机,中医证候特点、辨证论治上提出了许多有益的见解与认识。吴生元教授认为该病的发作是由于风寒湿邪阻痹经脉,夹内在痰湿相互交作,邪气不得外散,郁遏化热于皮肤腠理而导致急性关节肿痛。由于寒热交织,在里为寒湿阻痹,经脉气血不通,在表为痰湿郁热蕴结不得外散,而发此病。
目前临床上常用抗痛风药目前品种不多,临床治疗主要以秋水仙碱、非甾体类抗炎药、激素、促进尿酸排泄药(如丙磺舒、磺吡酮及苯溴马隆)和抑制尿酸合成药(别嘌呤醇)为主。这些药物在治疗上都有缺陷。疗效差、副作用大成为其临床应用的瓶颈。
发明内容
本发明旨在提供一种治疗痛风的药物组合物。
为实现上述发明目的,本发明一种治疗痛风的药物组合物,其具体方案为:
本发明所述一种治疗痛风的药物组合物,其特征在于该药物组合物处方重量份数计为:忍冬藤1-15份,虎杖1-10份,茯苓1-10份,伸筋草1-10份,黄芪1-10份,淫羊藿1-8份,威灵仙1-8份,车前子1-8份,何首乌1-8份,防风1-8份,甘草1-5份。
本发明所述一种治疗痛风的药物组合物,其特征在于该药物组合物处方重量份数计为:忍冬藤3-10份,虎杖2-8份,茯苓2-8份,伸筋草2-8份,黄芪2-8份,淫羊藿2-6份,威灵仙2-6份,车前子2-6份,何首乌2-6份,防风2-6份,甘草1-3份。。
本发明所述一种痛风的药物组合物,其特征在于该药物组合物重量份数计为:忍冬藤6份,虎杖4份,茯苓4份,伸筋草4份,黄芪4份,淫羊藿3份,威灵仙3份,车前子3份,何首乌3份,防风3份,甘草1.8份。
本发明任一项所述的中药组合物的制剂,其特征在于,所述制剂为口服制剂。 本发明所述的制剂,其特征在于,所述制剂由中药组合物与药学上可接受的载体组成,剂型包括水煎剂、丸剂、片剂、胶囊剂、颗粒剂、冲剂和口服液。 进一步地,本发明所述的制剂,其特征在于,所述制剂为水煎剂。
本发明所述的制剂,其特征在于,所述水煎剂的制备方法为:将原药材加8~10倍质量的水,煎煮1~2小时,过滤;药渣再加3~5倍质量的水,煎煮30~40分钟,过滤;合并两次滤液,即得。
本发明所述的制剂,其特征在于,所述水煎剂的制备方法为:将原药材加10倍质量的水,煎煮1.5小时,过滤;药渣再加5倍质量的水,煎煮30分钟,过滤;合并两 次滤液,即得。
本发明所述所述的中药组合物在制备治疗痛风药物中的应用。
本发明处方各组分药理分析:
忍冬藤:忍冬藤又名大薜荔、水杨藤、千金藤,多年生半常绿缠绕灌木,茎中空,幼枝密生短柔毛。味甘,性寒,具有清热解毒,疏风通络的疗效。可用于温病发热,疮痈肿毒,热毒血痢,风湿热痹。
虎杖:味苦,性平,祛风除湿,破血通经,消炎止痛。
茯苓:味甘、淡,性平,归心、肺、脾、肾经。利水渗湿,健脾,宁心。
伸筋草:味苦、辛、性温。祛风散寒、除湿消肿、舒筋活血。
黄芪:味甘,性微温。能补脾益气,补肺固表,利尿消肿。
淫羊藿:味辛、性温。补肝肾,强筋骨,助阳益精,祛风湿。
威灵仙:味辛、咸,性温。祛风除湿,通络止痛。用于风湿痹痛,肢体麻木,筋脉拘挛,屈伸不利,骨哽咽喉。
车前子:味甘,微寒,清热利尿;渗湿止泻;明目;祛痰。
何首乌:味苦、甘、涩,微温,具有补肝、益肾、养血、祛风等功效。
防风:味辛、甘,温。解表祛风,胜湿,止痉。
甘草,味甘平,入脾、胃经,补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。
本发明的有益效果在于:本发明所述的中药组合物,根据“木郁达之”,“结者散之”的原则,利用本发明药物组合物疏风通络,祛风除湿进行辩证施治,再采取调整生活规律,劳逸结合,低脂饮食等有利于建立愉快、规律的生活和工作秩序,可以对痛风达到标本兼治的功效。
具体实施方式
下面实施例只为进一步说明本发明,不以任何形式限制本发明范围。
实施例1 本发明组合物汤剂处方及制备方法:取忍冬藤30克,虎杖20克,茯苓20克,伸筋草20克,黄芪20克,淫羊藿15克,威灵仙15克,车前子15克,何首乌15克,防风15克,甘草9克。混合,向原药材中加10倍质量的水,煎煮1.5小时,过滤;药渣再加5倍质量的水,煎煮30分钟,过滤;合并两次滤液,制成水煎剂。
实施例2 本发明组合物汤剂处方及制备方法:忍冬藤30克,虎杖15克,茯苓15克,伸筋草20克,黄芪15克,淫羊藿10克,威灵仙10克,车前子10克,何首乌10克,防风10克,甘草6克。混合,向原药材中加10倍质量的水,煎煮1.5小时,过滤;药渣再加5倍质量的水,煎煮30分钟,过滤;合并两次滤液,制成水煎剂。
实施例3本发明组合物胶囊剂处方及制备方法:取忍冬藤30克,虎杖20克,茯苓20克,伸筋草20克,黄芪20克,淫羊藿15克,威灵仙15克,车前子15克,何首乌15克,防风15克,甘草9克。混合,向原药材中加10倍质量的水,煎煮1.5小时,过滤;药渣再加5倍质量的水,煎煮30分钟,过滤;合并两次滤液,减压浓缩至相对密度1.20~1.30,得水提液稠膏。 稠膏中加入适当比例的辅料,辅料拟选用蔗糖或乳糖(无糖型颗粒选用甘露醇、阿斯巴甜、甜菊糖)、糊精(预交化淀粉)、羧甲基纤维素钠(聚维酮)、羧甲淀粉钠(交联聚维酮、低取代羟丙纤维素)搅拌均匀,制得制得软材。 过24目筛,得湿颗粒。50~60℃干燥,干颗粒冷却后分别过24目筛整粒,外加硬脂酸镁(微粉硅胶),装胶囊,即得。
实施例4本发明组合物颗粒剂处方及制备方法:取忍冬藤30克,虎杖20克,茯苓20克,伸筋草20克,黄芪20克,淫羊藿15克,威灵仙15克,车前子15克,何首乌15克,防风15克,甘草9克。混合,向原药材中加10倍质量的水,煎煮1.5小时,过滤;药渣再加5倍质量的水,煎煮30分钟,过滤;合并两次滤液,减压浓缩至相对密度1.20~1.30,得水提液稠膏。稠膏中加入适当比例的辅料,辅料拟选用蔗糖或乳糖(无糖型颗粒选用甘露醇、阿斯巴甜、甜菊糖)、糊精(预交化淀粉)、羧甲基纤维素钠(聚维酮)搅拌均匀,制得制得软材。 过10目筛,得湿颗粒。50~60℃干燥,干颗粒冷却后分别过10目筛和65目筛整粒,即得。
实施例5本发明组合物冲剂处方及制备方法:取人参3g,茯苓3 g,熟地黄3 g,贝母3 g,炒山栀3 g,白术4.5 g,当归4.5 g,柴胡2.4 g,牡丹皮2.4 g,川芎2.4 g,陈皮2.4 g,甘草1.5 g,混合,烘干,研磨粉碎。水提取两次,第一次加10倍量水提取1h,滤过,药渣再加8 倍量水提取1h,滤过,合并两次滤液。减压浓缩至相对密度1.20~1.30,得水提液稠膏。 稠膏中加入适当比例的辅料,辅料拟选用蔗糖或乳糖(无糖型颗粒选用甘露醇、阿斯巴甜、甜菊糖)、糊精(可溶性淀粉、羧甲基纤维素钠、聚维酮)搅拌均匀,制得制得软材。挤压过10目筛,得湿颗粒。50~60℃干燥,干颗粒冷却后分别过10目筛和65目筛整粒,制成粉剂或颗粒状冲剂。
实施例6 本发明组合物片剂处方及制备方法:取人参3g,茯苓3 g,熟地黄3 g,贝母3 g,炒山栀3 g,白术4.5 g,当归4.5 g,柴胡2.4 g,牡丹皮2.4 g,川芎2.4 g,陈皮2.4 g,甘草1.5 g,混合,烘干,研磨粉碎。水提取两次,第一次加10倍量水提取1h,滤过,药渣再加8 倍量水提取1h,滤过,合并两次滤液。减压浓缩至相对密度1.20~1.30,得水提液稠膏。 稠膏中加入适当比例的辅料,辅料拟选用蔗糖或乳糖(无糖型颗粒选用甘露醇、阿斯巴甜、甜菊糖)、糊精(预交化淀粉)、羧甲基纤维素钠(聚维酮)、羧甲淀粉钠(交联聚维酮、低取代羟丙纤维素)搅拌均匀,制得制得软材。挤压过24目筛,得湿颗粒。50~60℃干燥,干颗粒冷却后分别过24目筛整粒,外加硬脂酸镁(微粉硅胶)压片,即得。
以上详细描述了本发明的较佳具体实施例。应当理解,本领域的普通技术人员无需创造性劳动就可以根据本发明的构思作出诸多修改和变化。因此,凡本技术领域中技术人员依本发明的构思在现有技术的基础上通过逻辑分析、推理或者有限的实验可以得到的技术方案,皆应在由权利要求书所确定的保护范围内。
Claims (9)
1.一种治疗痛风的药物组合物,其特征在于该药物组合物处方重量份数计为:忍冬藤1-15份,虎杖1-10份,茯苓1-10份,伸筋草1-10份,黄芪1-10份,淫羊藿1-8份,威灵仙1-8份,车前子1-8份,何首乌1-8份,防风1-8份,甘草1-5份。
2.根据权利要求1所述一种治疗痛风的药物组合物,其特征在于该药物组合物处方重量份数计为:忍冬藤3-10份,虎杖2-8份,茯苓2-8份,伸筋草2-8份,黄芪2-8份,淫羊藿2-6份,威灵仙2-6份,车前子2-6份,何首乌2-6份,防风2-6份,甘草1-3份。
3.根据权利要求1所述一种痛风的药物组合物,其特征在于该药物组合物重量份数计为:忍冬藤6份,虎杖4份,茯苓4份,伸筋草4份,黄芪4份,淫羊藿3份,威灵仙3份,车前子3份,何首乌3份,防风3份,甘草1.8份。
4.根据权利要求1-3任一项所述的中药组合物的制剂,其特征在于,所述制剂为口服制剂。
5.根据权利要求4所述的制剂,其特征在于,所述制剂由中药组合物与药学上可接受的载体组成,剂型包括水煎剂、丸剂、片剂、胶囊剂、颗粒剂、冲剂和口服液。
6.根据权利要求5所述的制剂,其特征在于,所述制剂为水煎剂。
7.根据权利要求6所述的制剂,其特征在于,所述水煎剂的制备方法为:将原药材加8~10倍质量的水,煎煮1~2小时,过滤;药渣再加3~5倍质量的水,煎煮30~40分钟,过滤;合并两次滤液,即得。
8.根据权利要求7所述的制剂,其特征在于,所述水煎剂的制备方法为:将原药材加10倍质量的水,煎煮1.5小时,过滤;药渣再加5倍质量的水,煎煮30分钟,过滤;合并两 次滤液,即得。
9.权利要求1-3任一项所述的中药组合物在制备治疗痛风药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510062971.3A CN104523873A (zh) | 2015-02-08 | 2015-02-08 | 一种治疗痛风的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510062971.3A CN104523873A (zh) | 2015-02-08 | 2015-02-08 | 一种治疗痛风的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104523873A true CN104523873A (zh) | 2015-04-22 |
Family
ID=52839629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510062971.3A Pending CN104523873A (zh) | 2015-02-08 | 2015-02-08 | 一种治疗痛风的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104523873A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105748611A (zh) * | 2016-03-28 | 2016-07-13 | 张艳娟 | 一种治疗高尿酸血症的药物组合物 |
CN105902635A (zh) * | 2016-06-29 | 2016-08-31 | 骆彩林 | 一种胡蜂药酒及其制作方法 |
CN117338886A (zh) * | 2023-08-25 | 2024-01-05 | 黑龙江珍宝岛药业股份有限公司 | 一种治疗痛风病的中药组合物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101524494A (zh) * | 2009-05-05 | 2009-09-09 | 陆玉敏 | 一种治疗痛风的药物 |
CN103920117A (zh) * | 2014-04-15 | 2014-07-16 | 韩世昌 | 一种治疗痛风的中药组合物及其制备方法 |
-
2015
- 2015-02-08 CN CN201510062971.3A patent/CN104523873A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101524494A (zh) * | 2009-05-05 | 2009-09-09 | 陆玉敏 | 一种治疗痛风的药物 |
CN103920117A (zh) * | 2014-04-15 | 2014-07-16 | 韩世昌 | 一种治疗痛风的中药组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
沈丕安编著: "《中药不良反应与临床》", 31 October 2007, 第二军医大学出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105748611A (zh) * | 2016-03-28 | 2016-07-13 | 张艳娟 | 一种治疗高尿酸血症的药物组合物 |
CN105902635A (zh) * | 2016-06-29 | 2016-08-31 | 骆彩林 | 一种胡蜂药酒及其制作方法 |
CN117338886A (zh) * | 2023-08-25 | 2024-01-05 | 黑龙江珍宝岛药业股份有限公司 | 一种治疗痛风病的中药组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102657835B (zh) | 治疗高血压或/和类风湿性关节炎的组合物、药酒及其制备方法和应用 | |
CN103520696A (zh) | 一种治心气不足证型胸痹心痛的中药组方 | |
CN103110762A (zh) | 一种治疗骨折久不愈合的中药组合物 | |
CN104523873A (zh) | 一种治疗痛风的药物组合物 | |
CN104524159A (zh) | 一种治疗乳腺增生的药物组合物 | |
CN104984267A (zh) | 一种治疗肺癌的中药组合物 | |
CN104888131A (zh) | 一种治疗失眠的中药组合物 | |
CN103520668B (zh) | 一种治疗心气不足证型胸痹心痛的中药 | |
CN104042925A (zh) | 一种治疗痛风的中药组合物及其制备方法 | |
CN103690869B (zh) | 治疗肠易激综合征的中药及其制备方法 | |
CN104587281A (zh) | 一种治疗肝硬化的健脾利湿中药组合物及制备 | |
CN103405554B (zh) | 一种用于腹部手术术前清肠的药物 | |
CN103656199A (zh) | 一种治疗肾阴不足证型咳嗽的中药 | |
CN103432399B (zh) | 一种用于妇科手术术前清肠的药物 | |
CN105125860A (zh) | 一种有效治疗骨质疏松的制剂 | |
CN104922595A (zh) | 一种用于带状疱疹的中药制剂及其制备方法 | |
CN100333780C (zh) | 抗衰老中药药物及其制备方法 | |
CN103393936B (zh) | 一种用于晚期妊娠引产术前干预的药物 | |
CN104491830A (zh) | 一种防治结核病的中药组合物及其制备方法 | |
CN103405640B (zh) | 一种用于晚期妊娠引产术前的清肠颗粒制备方法 | |
CN103705831A (zh) | 一种治疗绝经前后诸证的药物组合物及其制备方法 | |
CN103800875A (zh) | 一种用于治疗慢性肾功能衰竭的中药及其制备方法 | |
CN104491237A (zh) | 一种中药制剂在制备治疗原发性高血压药物中的用途 | |
CN103417769A (zh) | 一种妇科术前口服清肠颗粒的制备方法 | |
CN103417772B (zh) | 一种妇科术前口服肠道准备药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150422 |